Novo Nordisk and Glooko advance their digital health collaboration with launch of unique integrated app for improved diabetes management

Novo Nordisk makes the app available for free

InDex Pharmaceuticals gets new patent granted in Europe

InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides additional protection for the use of cobitolimod for the treatment of inflammatory diseases.

Results from SWITCH Trials for Tresiba® Published in the Journal of the American Medical Association

InDex Pharmaceuticals enrolls first patient in the phase IIb study CONDUCT with cobitolimod

InDex Pharmaceuticals Holding AB (publ) today announced that the first patient has been enrolled in the clinical study CONDUCT – a phase IIb dose optimisation study with the drug candidate cobitolimod.

Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes

FDA posts briefing materials prior to Advisory Committee meeting for Victoza® label update

Novo Nordisk today announced that the US Food and Drug Administration has published the briefing documents ahead of the Advisory Committee meeting to discuss the supplemental New Drug Application for approval of Victoza injection.